US biotech major Regeneron chooses Hyderabad for its Global Capability Centre
Regeneron Pharmaceuticals will set up a Global Capability Centre in Hyderabad, expected to be operational in the second half of 2026 and to grow to hundreds of jobs.
Regeneron Pharmaceuticals, Inc., the US biotechnology company, has announced that it will set up a Regeneron Global Capability Centre (GCC) in Hyderabad as part of the expansion of its global operations and business functions.
The GCC is expected to be operational in the second half of 2026 and to grow to hundreds of jobs over the coming years as it takes on capabilities across Regeneron’s global functions. It builds on the presence the company has had in India since 2022.
Founded and led by physician-scientists, Regeneron has 15 approved or authorised medicines and close to 50 product candidates in its pipeline. Hyderabad was chosen for its deep talent pool in biotechnology, artificial intelligence, digital and analytics, and for an ecosystem that already hosts more than 450 GCCs.